Devyser´s annual report 2024 has today been published on the company´s website.The report is available on: https://investors.devyser.com/en/reports-presentationsThe financial year covers…
The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Devyser Genomic Laboratories, Roswell, Georgia, based on the results of a recent…
Devyser a leading provider of genetic testing solutions, has been awarded a significant tender for the supply of its comprehensive next-generation sequencing (NGS) tests for critical…
Devyser issues a correction to the year-end report for 2024 that was sent out earlier today, where an incorrect distribution of the quarter's net sales between direct sales and…
“Net sales increased during the fourth quarter by 41.5 percent to SEK 64.2 million, compared with the corresponding quarter of 2023. The growth and strong performance are a result of…
On Thursday February 13 at 13:00 CET, Devyser Diagnostics AB will host an online presentation of its Q4 2024 report (which will have been published earlier on February 13 at 10:00…
Devyser has launched Devyser Thalassemia v2, a next-generation sequencing (NGS) solution designed to further simplify genetic testing. The improved technology, will help broader screening…
Devyser has secured a tender for its cystic fibrosis NGS test, Devyser CFTR. The tender with Policlinico di Bari is valid for five years with an estimated total order value up to 5.4…
In light of this morning’s communication that Fredrik Alpsten is leaving his position as CEO of Devyser and to avoid speculation, Devyser is releasing a summary of the year-end report for…
Fredrik Alpsten and the Board of Directors of Devyser have now reached an agreement that he will leave his position as CEO of Devyser.Devyser's Board of Directors has initiated the…
